zoledronic acid has been researched along with epirubicin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andreadis, C; Charalampidou, M; Chouchos, N; Diamantopoulos, N; Mouratidou, D | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Budman, DR; Calabro, A | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Coleman, RE; Cross, SS; Evans, A; Freeman, JV; Hatton, MQ; Holen, I; Ingram, CE; Jolley, IJ; Mori, S; Syddall, SP; Wilson, C; Winter, MC | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Miura, D; Tanino, H | 1 |
| Deng, Y; Ding, J; Liu, X; Qin, Y; Song, Y; Sui, D; Tang, X; Wang, Y; Zhang, N | 1 |
1 review(s) available for zoledronic acid and epirubicin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for zoledronic acid and epirubicin
| Article | Year |
|---|---|
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follistatin; Humans; Imidazoles; Inhibins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Triple Negative Breast Neoplasms; Zoledronic Acid | 2015 |
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imidazoles; Mastectomy, Segmental; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Receptor, ErbB-2; Zoledronic Acid | 2017 |
9 other study(ies) available for zoledronic acid and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fluorouracil; Humans; Imidazoles; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Salvage Therapy; Tamoxifen; Zoledronic Acid | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Epirubicin; Liposomes; Mice; N-Acetylneuraminic Acid; Zoledronic Acid | 2021 |